Genmab — November 2018
-
God morgen.
-
God morgen
-
Jeg har stor respekt for TA, men det skal blot anvendes brugbart og meningsfuld. Evt til at analysere trenden om end det kan være svært med aktier, som handles på forventninger og nyhedsflow. TA er brugbart - så absolut, men at sætte sig mellem 2 stole er i min verden ikke raketvidenskab, men en let udmelding. Hvis ikke den går op, falder den
-
Er der kommet noget ud vedr. retsmødet i gpr?
-
Will MorphoSys win the Darzalex patent case against Janssen and Genmab? — Markman Advisors
In 2016, MorphoSys ($MOR) sued Janssen ($JNJ) and Genmab for patent infringement. MorphoSys claims that Janssen’s anti-CD38 antibody, Darzalex®, infringes three of its patents. The case is scheduled to go to trial in February 2019. The stakes are big because the patents purport to cover the actual protein used in Darzalex®, which could mean material royalty rates on sales of Janssen’s drug. What are the strengths and weaknesses of each party’s case?
Markman Advisors (www.markmanadvisors.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind